Pregnancy outcome in a woman exposed to continuous intrathecal baclofen infusion

Muñoz, Francisco Calderón; Marco, David García; Pérez, Alfonso Verdú; Camacho, Manuela Martínez

doi:10.1345/1542-6270(2000)34<956a:poiawe>2.0.co;2

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,2 Oral baclofen therapy leads to high plasma levels (0.08 -0.4 mg/mL) and has been associated with neonatal withdrawal manifested as convulsions. 3 The ITB pump is Food and Drug Administration (FDA) approved for severe spasticity that is refractory to oral therapy.…”

Section: Introductionmentioning

confidence: 99%

Intrathecal baclofen pump – a viable therapeutic option in pregnancy

Tandon¹,

Hoskins²,

Azhar

2010

Obstet Med

View full text Add to dashboard Cite

Summary: Baclofen, a gamma-aminobutyric acid analogue, is used as a muscle relaxant and antispasmodic to relieve symptoms in patients with intractable spasticity arising from cerebral or spinal aetiology such as in traumatic brain injury or multiple sclerosis. As it is often used in women of reproductive age, it is imperative to know the safety and associated maternal and fetal risks. The Food and Drug Administration has assigned the drug to Pregnancy Category C because of the lack of controlled data in humans. Animal studies have revealed an increased incidence of omphalocele if used in doses several times the recommended human dose. Baclofen should only be given during pregnancy when the benefits outweigh the risks. Baclofen is considered compatible with breast feeding by the American Academy of Pediatrics.

show abstract

Section: Introductionmentioning

confidence: 99%